Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 78, 2018 - Issue 4
Submit an article Journal homepage
89
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Are age-specific reference ranges for CYFRA 21-1 appropriate?

Gustav MikkelsenDepartment of Clinical Chemistry, Trondheim University Hospital, Trondheim, Norway;Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayCorrespondence[email protected]
,
Arne ÅsbergDepartment of Clinical Chemistry, Trondheim University Hospital, Trondheim, Norway
&
Gunhild Garmo HovDepartment of Clinical Chemistry, Trondheim University Hospital, Trondheim, Norway;Norwegian University of Science and Technology, Trondheim, Norway
Pages 335-336 | Received 16 Feb 2018, Accepted 04 Mar 2018, Published online: 13 Mar 2018

References

  • Zhao B, Zhang M, Liu D, et al. Establishment of reference interval for the tumour marker serum CYFRA 21-1 in healthy Chinese Han ethnic adults. Scand J Clin Lab Invest. 2018. [Epub ahead of print]. doi: 10.1080/00365513.2018.1426105
  • Sarwar M, Tomiyoshi K, Inoue T, et al. CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay. Ann Nucl Med. 1994;8:301–306.
  • Molina R, Agusti C, Filella X, et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumor Biol. 1994;15:318–325.
  • Rastel D, Ramaioli A, Cornillie F, et al. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer. 1994;30A:601–606.
  • Xiaofang Y, Yue Z, Xialian X, et al. Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest. 2007;67:661–667.
  • Tramonti G, Ferdeghini M, Donadio C, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect Prev. 2000;24:86–90.
  • Tong HL, Dong ZN, Wen XY, et al. Impact of chronic kidney disease on serum tumor markers concentrations. Chin Med J. 2013;126:274–279.
  • Mikkelsen G, Asberg A, Hultstrom ME, et al. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease. Int J Biol Markers. 2017;32:e461–e4e6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.